In one paragraphArticle in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Florian PuhmDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0001-5699-6626 Isabelle AllaeysDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0003-4697-046X Eleonora PetitoDepartment of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy (E.P., L.B., E.B.).ORCID 0000-0003-4921-8687 Yaqiu SangDepartment of Pathology and Laboratory Medicine and University North Carolina (UNC) Blood Research Center, University of North Carolina at Chapel Hill (Y. Sang, A.S.W.).ORCID 0000-0001-5147-989X Florian TupinDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.
Ana Dos Santos Pereira AndradeDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0001-9724-4164 Etienne DoréDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0002-2347-5012 Isabelle DubucDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0003-3432-1980 Myriam VaillancourtDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.
Mélanie DieudéCentre Hospitalier de l'Université de Montréal (CRCHUM), Québec City, Québec, Canada (M.D., M.-J.H.).ORCID 0000-0002-9300-4232 Marie-Josée HébertCentre Hospitalier de l'Université de Montréal (CRCHUM), Québec City, Québec, Canada (M.D., M.-J.H.).ORCID 0000-0002-6234-682X Bogdan I FloreaGorlaeus Laboratories, Leiden Institute of Chemistry and Netherlands Proteomics Centre (B.I.F.).ORCID 0000-0001-7114-2266 Yotis SenisCentre for Cardiovascular and Nutrition Research, Institut National de la Santé et de la Recherche 1263, Faculty of Medicine, Aix-Marseille University, France (Y. Senis).
Paul R FortinDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0002-7278-2596 Alain R BrissonUnité Mixte de Recherche-Chimie et Biologie des Membranes et des Nano-objets (UMR-CBMN), Université de Bordeaux, Centre National de la Recherche Scientifique (CNRS), Institut Polytechnique de Bordeaux (IPB), Pessac, France (A.R.B.).ORCID 0000-0003-0342-352X Alisa S WolbergDepartment of Pathology and Laboratory Medicine and University North Carolina (UNC) Blood Research Center, University of North Carolina at Chapel Hill (Y. Sang, A.S.W.).ORCID 0000-0002-2845-2303 Loredana BuryDepartment of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy (E.P., L.B., E.B.).ORCID 0000-0003-0333-0948 Louis FlamandDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0001-5010-4586 Eric BoilardDépartement de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine (F.P., I.A., F.T., A.d.S.P.A., E.D., I.D., M.V., P.R.F., L.F., E.B.), Université Laval, Québec City, Québec, Canada.ORCID 0000-0001-6319-6432 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundReceptors that bind antibodies are essential for protective adaptive immune responses against antibody-opsonized pathogens, yet their engagement by antibody-autoantigen complexes can drive chronic inflammation in autoimmune diseases. Megakaryocytes, the precursor cells of platelets, express such receptors. However, their response to immunoglobulin G antibodies remains unclear.
methodsWe used both systemic lupus erythematosus and COVID-19 as relevant examples of autoimmune and infection-driven contexts in which antibodies are involved to characterize human and mouse megakaryocyte responses.
resultsWe found that megakaryocytes internalized immune complexes composed of autoantigens or SARS-CoV-2. In both human and mouse megakaryocytes, immune complexes triggered the release of chemokines and procoagulant extracellular vesicles. This process required FcγRIIA (Fc gamma receptor IIA) engagement, downstream Syk (spleen tyrosine kinase) signaling, and protein translation. A detailed analysis revealed that megakaryocyte-derived extracellular vesicles did not contain organelles and were largely indistinguishable from a subset of small-sized extracellular vesicles released by activated platelets. In FcγRIIA-transgenic mice, we analyzed megakaryocytes in both the bone marrow and lungs in a lupus model, whereas megakaryocytes were examined in the lungs in a COVID-19 model. In all cases, immunoglobulins were detected in close proximity to FcγRIIA-expressing megakaryocytes. Notably, the chemokine CXCL2 (C-X-C motif ligand-2) was increased in FcγRIIA-expressing mice under disease conditions. Tissue spatial analysis revealed that CXCL2 predominantly localized to megakaryocytes, supporting these cells as a major source. Furthermore, SARS-CoV-2 stimulated megakaryocytes to release CXCL2 only in the presence of IgG from SARS-CoV-2 immune individuals, and this response was strictly dependent on FcγRIIA expression.
conclusionsThese findings suggest that megakaryocytes contribute to adaptive immune responses through FcγRIIA-mediated signaling.
Indexed as
Antigen-Antibody ComplexCOVID-19MegakaryocytesSARS-CoV-2AnimalsAutoantigensHumansImmunoglobulin GLupus Erythematosus, SystemicMiceMice, Inbred C57BLMice, TransgenicReceptors, IgGSignal TransductionSyk KinaseAntigen-Antibody ComplexAutoantigensFc gamma receptor IIAImmunoglobulin GReceptors, IgGSyk Kinaseadaptive immunityautoantigensextracellular vesiclemegakaryocytesmice
Identifiers
PMID42299675
PMCPMC13374656
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390